1. Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus

   • Marcel M. C. Hovens
   • Jouke T. Tamsma
   • Menno V. Huisman

   Leading Article 17 September 2012 Pages: 433 - 445

   

2. New Treatment Modalities for Vitiligo

   • Kresimir Kostovic
   • Aida Pasic

   Leading Article 17 September 2012 Pages: 447 - 459

   

3. Adverse Effects and Drug Interactions of Antithrombotic Agents Used in Prevention of Ischaemic Stroke

   • Jesse Weinberger

   Review Article 17 September 2012 Pages: 461 - 471

   

4. An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis

   • Nick J. Bansback
   • Dean A. Regier
   • Carlo A. Marra

   Review Article 17 September 2012 Pages: 473 - 496

   

5. Management of Sight-Threatening Uveitis

   • Matthias D. Becker
   • Justine R. Smith
   • Christoph Fiehn

   Review Article 17 September 2012 Pages: 497 - 519

   

6. Peginterferon α-2a (40KD) Plus Ribavirin

   • Gillian M. Keating
   • Greg L. Plosker

   Adis Drug Evaluation 17 September 2012 Pages: 521 - 536

   

7. Candesartan Cilexetil

   • Caroline Fenton
   • Lesley J. Scott

   Adis Drug Evaluation 17 September 2012 Pages: 537 - 558

   

8. Paricalcitol

   • Dean M. Robinson
   • Lesley J. Scott

   Adis Drug Evaluation 17 September 2012 Pages: 559 - 576

   

9. 5-Lipoxygenase as a Putative Mechanism of NSAID-Related Psychiatric Adverse Events

   • Radmila Manev
   • Hari Manev

   Letter to the Editor 17 September 2012 Pages: 577 - 577